Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 580

1.

Health-related quality of life outcomes of adalimumab for patients with early rheumatoid arthritis: results from a randomized multicenter study.

Strand V, Rentz AM, Cifaldi MA, Chen N, Roy S, Revicki D.

J Rheumatol. 2012 Jan;39(1):63-72. doi: 10.3899/jrheum.101161. Epub 2011 Nov 1.

2.

[Adalimumab plus methotrexate for the treatment of rheumatoid arthritis: a multi-center randomized, double-blind, placebo-controlled clinical study.].

Huang F, Zhang FC, Bao CD, Tao Y, Gu JR, Xu JH, Zhu P, Xu HJ, Zhang ZY, Zhao DB, Wu DH.

Zhonghua Nei Ke Za Zhi. 2009 Nov;48(11):916-21. Chinese.

PMID:
20079321
3.

The effect of intravenous golimumab on health-related quality of life in rheumatoid arthritis: 24-week results of the phase III GO-FURTHER trial.

Bingham CO 3rd, Weinblatt M, Han C, Gathany TA, Kim L, Lo KH, Baker D, Mendelsohn A, Westhovens R.

J Rheumatol. 2014 Jun;41(6):1067-76. doi: 10.3899/jrheum.130864. Epub 2014 May 1.

PMID:
24786931
4.

Effect of rituximab on physical function and quality of life in patients with rheumatoid arthritis previously untreated with methotrexate.

Rigby W, Ferraccioli G, Greenwald M, Zazueta-Montiel B, Fleischmann R, Wassenberg S, Ogale S, Armstrong G, Jahreis A, Burke L, Mela C, Chen A.

Arthritis Care Res (Hoboken). 2011 May;63(5):711-20. doi: 10.1002/acr.20419.

5.
6.

Effect of golimumab on patient-reported outcomes in rheumatoid arthritis: results from the GO-FORWARD study.

Genovese MC, Han C, Keystone EC, Hsia EC, Buchanan J, Gathany T, Murphy FT, Wu Z, Parasuraman S, Rahman MU.

J Rheumatol. 2012 Jun;39(6):1185-91. doi: 10.3899/jrheum.111195. Epub 2012 Apr 15.

PMID:
22505702
7.

Improved health outcomes with etanercept versus usual DMARD therapy in an Asian population with established rheumatoid arthritis.

Bae SC, Gun SC, Mok CC, Khandker R, Nab HW, Koenig AS, Vlahos B, Pedersen R, Singh A.

BMC Musculoskelet Disord. 2013 Jan 8;14:13. doi: 10.1186/1471-2474-14-13.

8.

Patient-reported outcomes from a phase 3 study of baricitinib versus placebo or adalimumab in rheumatoid arthritis: secondary analyses from the RA-BEAM study.

Keystone EC, Taylor PC, Tanaka Y, Gaich C, DeLozier AM, Dudek A, Zamora JV, Cobos JAC, Rooney T, Bono S, Arora V, Linetzky B, Weinblatt ME.

Ann Rheum Dis. 2017 Nov;76(11):1853-1861. doi: 10.1136/annrheumdis-2017-211259. Epub 2017 Aug 10.

9.

Rapid and sustained improvements in health-related quality of life, fatigue, and other patient-reported outcomes in rheumatoid arthritis patients treated with certolizumab pegol plus methotrexate over 1 year: results from the RAPID 1 randomized controlled trial.

Strand V, Mease P, Burmester GR, Nikaï E, Coteur G, van Vollenhoven R, Combe B, Keystone EC, Kavanaugh A.

Arthritis Res Ther. 2009;11(6):R170. doi: 10.1186/ar2859. Epub 2009 Nov 12.

10.

Sarilumab plus methotrexate improves patient-reported outcomes in patients with active rheumatoid arthritis and inadequate responses to methotrexate: results of a phase III trial.

Strand V, Kosinski M, Chen CI, Joseph G, Rendas-Baum R, Graham NM, van Hoogstraten H, Bayliss M, Fan C, Huizinga T, Genovese MC.

Arthritis Res Ther. 2016 Sep 6;18:198. doi: 10.1186/s13075-016-1096-9.

12.
13.

Efficacy, pharmacokinetic, and safety assessment of adalimumab, a fully human anti-tumor necrosis factor-alpha monoclonal antibody, in adults with rheumatoid arthritis receiving concomitant methotrexate: a pilot study.

Weisman MH, Moreland LW, Furst DE, Weinblatt ME, Keystone EC, Paulus HE, Teoh LS, Velagapudi RB, Noertersheuser PA, Granneman GR, Fischkoff SA, Chartash EK.

Clin Ther. 2003 Jun;25(6):1700-21.

PMID:
12860493
14.

Clinical, functional, and radiographic benefits of longterm adalimumab plus methotrexate: final 10-year data in longstanding rheumatoid arthritis.

Keystone EC, van der Heijde D, Kavanaugh A, Kupper H, Liu S, Guérette B, Mozaffarian N.

J Rheumatol. 2013 Sep;40(9):1487-97. doi: 10.3899/jrheum.120964. Epub 2013 Jul 1.

16.

Less radiographic progression with adalimumab plus methotrexate versus methotrexate monotherapy across the spectrum of clinical response in early rheumatoid arthritis.

Emery P, Genovese MC, van Vollenhoven R, Sharp JT, Patra K, Sasso EH.

J Rheumatol. 2009 Jul;36(7):1429-41. doi: 10.3899/jrheum.081018. Epub 2009 Apr 15. Erratum in: J Rheumatol. 2010 Oct;37(10):2198. J Rheumatol. 2010 May;37(5):1081.

PMID:
19369462
17.

Treatment of rheumatoid arthritis patients with abatacept and methotrexate significantly improved health-related quality of life.

Emery P, Kosinski M, Li T, Martin M, Williams GR, Becker JC, Blaisdell B, Ware JE Jr, Birbara C, Russell AS.

J Rheumatol. 2006 Apr;33(4):681-9. Epub 2006 Mar 1.

PMID:
16568505
18.
19.

Longterm effect of delaying combination therapy with tumor necrosis factor inhibitor in patients with aggressive early rheumatoid arthritis: 10-year efficacy and safety of adalimumab from the randomized controlled PREMIER trial with open-label extension.

Keystone EC, Breedveld FC, van der Heijde D, Landewé R, Florentinus S, Arulmani U, Liu S, Kupper H, Kavanaugh A.

J Rheumatol. 2014 Jan;41(1):5-14. doi: 10.3899/jrheum.130543. Epub 2013 Nov 15.

20.

Supplemental Content

Support Center